Erythromycin Delayed-Release Tablets 333mg from Canada
Enteric-coated delayed-release tablets with 333mg erythromycin base to protect gastric mucosa, for duodenal ulcer treatment in retail bottles. HTS 3004.20.0020 covers formulated antibiotic dosage forms regardless of release mechanism.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Dissolution profile testing per USP; acid resistance certification
• DESI compliance for older antibiotics
• Avoid moisture during shipping